bromantane vs Noopept (omberacetam; GVS-111)

bromantane (B-tier) vs Noopept (omberacetam; GVS-111) (B-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

bromantane — tier B

a Russian antiasthenic CNS drug with older human studies in illness-related fatigue, incomplete modern replication, no traceable primary human half-life source, and in-competition WADA prohibition.

bromantane has a real Russian drug and human-study record for asthenia, but that record does not establish healthy cognitive enhancement, long-term safety, or the internet's preferred half-life number.

728 patients in the largest indexed Russian asthenia study · half-life not structured; the repeated 11.21-hour human claim was not traced to an accessible primary PK source · focus

Noopept (omberacetam; GVS-111) — tier B

a Russian cognitive drug with one small active-comparator clinical study, a short human PK poster, substantial animal work, and major US supplement-identity problems.

Noopept has a real foreign-drug identity and limited human data, but the efficacy record is much smaller than its reputation and the US supplement market adds a separate product-quality failure.

53 participants in the main indexed active-comparator study · half-life 22.05 plus or minus 14.37 minutes in a sparsely reported human conference abstract · focus

at a glance

• bromantane: tier B · 728 patients in the largest indexed Russian asthenia study
• Noopept (omberacetam; GVS-111): tier B · 53 participants in the main indexed active-comparator study

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.